Eight new drugs for orphan designation
This article was originally published in Scrip
The EU's Committee for Orphan Medicinal Products (COMP) adopted eight positive opinions on orphan drug designation – including its 26th and 27th positive opinion for cystic fibrosis, at its July plenary meeting.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.